Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients

G. A. BALOGH, D. MAILO, H. NARDI, M. M. CORTE, E. VINCENT, E. BARUTTA, G. LIZARRAGA, P. LIZARRAGA, H. MONTERO, R.GENTILI

Experimental and Therapeutic Medicine

http://www.spandidos-publications.com/

Lugar: ATHENAS; Año: 2010 vol. 1 p. 357 - 361

1792-0981

The aim of this study was to compare the sensitivity of the serological level of anti-p53 antibodies in breast cancer patients and to correlate its expression level with patient age, histological stage and grade of tumor differentiation. Total p53 protein expression (mutant and wild-type) was also determined in the breast cancer tissues using immunohistochemistry (IHC). The serological levels of mutant p53 expression were found to be age-dependent, reaching the highest level at 50 years of age. Faint or low detection was observed in patients ¡Ü30 years of age. Anti-p53-antibodies were detected in patients ¡Ü40 and ¡Ý61 years of age. The serological levels of mutant p53 protein were highly detected in all stages of breast cancer, including the early stages. However, anti-p53 antibodies reached a high level of detection only in stage III breast carcinomas. No expression was found in patients with benign breast disease. The detection of p53 mutations was dependent on the grade of tumor differentiation, achieving the highest level in the poorly differentiated breast carcinomas. Results from IHC were highly correlated with serological p53 mutational analysis. Our findings indicate that mutant p53 in serum is a promising novel parameter for the evaluation of cellular biology and the prognosis of breast cancer from its early stages using blood samples. Anti-p53 antibodies were demonstrated to be less sensitive in this study. It is also possible to use the expression of mutant p53 protein as a molecular marker to differentiate benign breast disease from breast carcinoma prior to surgery.